Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

PRHSX vs. SWHFX: which is better?

Bottom line

PRHSX vs SWHFX: the short answer

PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 73% by weight.

But PRHSX is far broader, holding 279 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.

SWHFX is cheaper at 0.8% vs 0.83% — a difference of $3.00 a year per $10,000 invested.

Over five years, SWHFX returned +6.5% a year vs +4.2% for PRHSX.

Updated Nov 19, 2026

PRHSX vs SWHFX side by side

PRHSXSWHFX
TypeMutual fundMutual fund
Fund familyT. Rowe PriceSchwab
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.83%0.8%
Annual cost per $10k$83$80
10-yr cost on $10k (prospectus)$1,025$990
Max front load——
12b-1 fee—0%
1-yr return+17.7%+15.9%
5-yr return (annualized)+4.2%+6.5%
10-yr return (annualized)+9.1%+8.1%
Best quarter+23.5%+15.3%
Worst quarter−15.8%−12.1%
Net assets (fund)$11.9B$642.3M
Number of holdings27980
Portfolio turnover62%41%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearPRHSXSWHFXDifference
2025+17.7%+15.9%+1.8%
2024+1.8%+0.1%+1.7%
2023+3.1%+0.7%+2.4%
2022−12.2%−4.7%−7.5%
2021+13.3%+23.3%−10.0%
2020+30.1%+12.9%+17.3%
2019+29.1%+17.6%+11.5%
2018+1.2%+4.0%−2.8%
2017+28.0%+20.2%+7.8%
2016−10.4%−4.4%−6.0%

Source: Fund prospectus bar charts

Holdings overlap

14 of PRHSX's top 25 holdings also appear in SWHFX's top 25.

Shared top holdings
HoldingPRHSXSWHFX
Eli Lilly & Co14.28%13.92%
Johnson & Johnson6.63%6.94%
Unitedhealth Group Inc5.99%4.74%
Abbvie Inc5.10%5.81%
Merck & Co. Inc.4.01%4.98%
Gilead Sciences Inc2.82%3.24%
Thermo Fisher Scientific Inc2.52%2.16%
Vertex Pharmaceuticals Inc2.28%1.89%
Bristol-myers Squibb Co2.11%2.44%
Abbott Laboratories1.89%1.60%
Amgen Inc1.82%2.58%
Stryker Corp1.78%2.11%
Elevance Health Inc1.53%1.45%
Danaher Corp1.43%1.47%

Source: SEC Form N-PORT

PRHSX top 10

  1. Eli Lilly & Co — 14.28%
  2. Johnson & Johnson — 6.63%
  3. Unitedhealth Group Inc — 5.99%
  4. Abbvie Inc — 5.10%
  5. Merck & Co. Inc. — 4.01%
  6. Gilead Sciences Inc — 2.82%
  7. Thermo Fisher Scientific Inc — 2.52%
  8. Vertex Pharmaceuticals Inc — 2.28%
  9. Bristol-myers Squibb Co — 2.11%
  10. Abbott Laboratories — 1.89%

SWHFX top 10

  1. Eli Lilly & Co — 13.92%
  2. Johnson & Johnson — 6.94%
  3. AbbVie Inc — 5.81%
  4. Merck & Co Inc — 4.98%
  5. UnitedHealth Group Inc — 4.74%
  6. Gilead Sciences Inc — 3.24%
  7. Novartis AG — 2.92%
  8. Amgen Inc — 2.58%
  9. Bristol-Myers Squibb Co — 2.44%
  10. Medtronic PLC — 2.29%

FAQ

What is the difference between PRHSX and SWHFX?
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and SWHFX (Schwab Health Care Fund) share a meaningful slice of their top holdings — about 73% by weight. But PRHSX is far broader, holding 279 positions to 80 for SWHFX, so beyond the top names it adds exposure SWHFX doesn't have.
Which is cheaper, PRHSX or SWHFX?
SWHFX has the lower expense ratio (0.8%).
Should I own both PRHSX and SWHFX?
Owning both adds little diversification because their portfolios overlap heavily; most investors pick one.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.